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ABSTRACT
Objectives: Postpartum hemorrhage (PPH) is the leading cause of maternal death, accounting for 1/4 of maternal deaths 
worldwide. Determining sensitive biomarkers in the peripheral blood to identify postpartum haemorrhage (PPH) is es-
sential for the early diagnosis and management of PPH. The purpose of this study is to identify predictive serum metabolic 
biomarkers of PPH. Thirty healthy pregnant women and 30 cases of postpartum hemorrhage were studied for our research. 
Material and methods: The serum metabolites of all pregnant were detected by liquid chromatography-quadruple 
time-of-flight mass spectrometry (LC-QTOFMS) and the corresponding biomarkers were identified. 
Results: 34 significantly altered metabolites in PPH-pre-group were identified. They were mainly involved in fatty acid, 
and glycerophospholipid metabolism.
Conclusions: The LysoPCs, PCs, PGs, PIs were effective biomarkers for identifying PPH. The disturbed signaling pathways, 
mTOR signaling, acute phase response signaling, AMPK signaling and eNOS signaling pathways might be related to the 
etiopathogenesis of PPH. Our study provided a valuable attempt to screen early diagnostic markers of PPH and to further 
understand its pathogenesis.
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INTRODUCTION
Postpartum haemorrhage is the leading cause of death 
during pregnancy and preterm birth, accounting for 1/4 of 
maternal deaths worldwide [1]. It is defined as blood loss 
of more than 500 mL after the birth of the genital tract 
(or > 1000 mL after a caesarean section). It is estimated that 
140,000 women die of PPH each year [2]. Of postpartum 
deaths, 45% occur within the first 24 hours and 66% occur 
within the first week. The prevalence of PPH worldwide 
is between 6% and 10% [3]. The reason for deaths of PPH 
is that is not easy to notice immediately or earlier which 
is important to early diagnosis and intervention for PPH. 
Women who have prolonged childbirth, multiple pregnan-
cies, amniotic fluid, and fetal macrosomia, obesity or fever 
during childbirth are at increased risk. Previous studies have 
identified risk factors associated with the PPH [4, 5], such as 
history of PPH, overdistended uterus, nullipara or low parity, 
multiple birth, high blood pressure, ante-partum hemor-
rhage and increased maternal BMI have been significantly 
associated with PPH [5]. While these associations are not the 
sensitive predictive biomarkers, women with these risk fac-
tors are not suffering from postpartum hemorrhage, while 
some pregnant women without these risk factors may be 
suffering from postpartum hemorrhage.
Metabolomics is a discipline that studies the changes 
of metabolites induced by physiological stimuli or genetic 
modifications in living systems [6]. Until now, metabolomics 
has been applied to identify early diagnostic markers of 
various diseases and study pathogenesis of them. Further-
more, metabolomics is a rapid method for qualitative and 
semiquantitative analysis of metabolites in cells, biological 
fluids and tissues. Due to its unique advantages and sig-
nificant efficiency, metabolomics has been widely used in 
studying diseases of obstetrics and gynecology in various 
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aspects. For example, a series of experimental investigations 
had been conducted on gestational diabetes mellitus [7, 8], 
preeclampsia [9, 10] and cancers [11, 12], and to identify the 
potential markers in maternal serum, plasma, amniotic fluid 
(AF), cord blood, urine, feces, trophocyte, or tissues. While 
until now, there is no metabolomics study of PPH for the 
early diagnostic biomarker identification before childbirth.
In our study, we first employed a LC-MS-based me-
tabolomics study to characterize the metabolic profiles of 
PPH-pre, and then used bioinformatics analysis software 
to identify corresponding pathogenesis of PPH. Our aim is 
to search for effective biomarkers and further understanding 
the pathogenesis of PPH.
MATERIAL AND METHODS
Patients
Pregnant women with no previous history of pregnan-
cies were included in our study. The subjects were assessed 
for their health status. Their weight and height information 
was also recorded, and body mass index was calculated to 
be kg/m2. These women were asked to fast for one hour 
prior to serum collection to prevent the effects of diet on 
metabolism. All subjects signed informed consent when 
they were admitted to this study. This study was approved by 
the research ethics committee of Tongren Hospital, School 
of Medicine, Shanghai Jiaotong University. Collection of 
pregnant women’s serum within 24 hours prior to the pro-
duction as the study subjects. After childbirth, calculation 
of the amount of bleeding in pregnant women with parturi-
tion. Women with total bleeding volume more than 500 mL 
following vaginal delivery were included as the PPH, and 
these serums collected within 24 hours prior to the produc-
tion were included as PPH-pre-group. The serum collected 
within 24 hours before the production from women with 
total bleeding volume less than 500 mL was included as con-
trol group. Lastly, 30 cases of postpartum hemorrhage and 
30 women in control group were collected. The patient’s age, 
gestational age, total blood loss during PPH were recorded.
Serum Sample Collection 
Venous blood was drawn into a non-heparin tube, 
placed for 20 minutes at 25°C, and then centrifuged for 
10 minutes at 3000 rpm. One Hundred μL serum samples 
were added with 300 μL methanol with internal stand-
ard (2-chlorobenzene alanine, 0.2 mg/mL) and then the 
sample was vortexed and placed for 1 min then the su-
pernatant was collected after a 12,000 rpm centrifuge for 
10 mins at 4°C. 
LC-Q-TOF/MS
A 3 μL aliquot of sample was injected into Agilent 
1290 LC-Agilent 6545 QTOF/MS (Agilent Technologies, 
Santa Clara, CA, USA). All samples were separated with 
a HSS T3 C18 column (100 mm × 2.1 mm, 1.7 μm, Waters, 
USA) and the column was heated at 45°C. The following 
gradient program was used water and acetonitrile. The 
elution procedure was 5% acetonitrile for 0–2 min; 2–95% 
acetonitrile 0.1% formic acid for 2–13 min; elution with 95% 
acetonitrile 0.1% formic acid for 13–15 min; post-time step 
for 3 min. The flow rate was 0.3 mL/min. Mass detection was 
operated with an electrospray source operating in either 
positive or negative ion mode. The mass spectrum param-
eters are set as follows: drying gas (N2) flow rate was set 
at 7 L/min; gas temperature was set at 330°C; pressure of 
nebulizer gas was 35 psig; Vcap was 4200V; fragmentor was 
165V; skimmer was 60V; scan range (m/z) was 80–1000. The 
MS/MS detection was used the targeted MS2 mode with 
collision energy 10EV, 20EV and 40EV. Serum samples were 
run randomly, and the quality control (QC) sample was 
analyzed every 10 serum samples. The analysis should be 
stopped when the QC sample was abnormal. Then rinse 
the column and ion source and correct the mass axis until 
the QC test was normal. 
Data Processing and Statistical Analysis 
The Agilent Mass Hunter Qualitative Analysis Software 
7.0 (Agilent Technologies, Palo Alto, CA, USA) was used for 
peak extraction, deconvolution and peak matching from 
the UPLC-QTOFMS ESI+ and ESI- raw data. After that a list 
of each peak detected was created including the retention 
time, m/z and ion intensity information of each ion. And then 
the SIMCA-P13.0 software (Umetrics AB, Umea, Sweden) 
was used for Principal component analysis (PCA) and partial 
least-squares discriminant analysis (PLS-DA). The default 
7-fold cross-validation was applied for guard against PLS-DA 
model over-fitting. Those significantly changed ions were 
identified and those with the VIP (variable importance in 
the projection)value more than 1 obtained from the PLS-DA 
model, as well as P < 0.05 obtained from the Student’s t test, 
were selected as potential biomarkers. Those ions were 
identified by comparison of exact molecular weight and 
fragment ion acquired in targeted MS/MS mode with the 
Human Metabolome Database (http://www.hmdb.ca/) and 
Metlin (https://metlin.scripps.edu/). Pathway analysis of the 
markers was used the Web-based software, MetaboAnalyst 
3.0 (http://www.metaboanalyst.ca/).
IPA Analysis
To systematically understand the biomarkers of PPH, we 
uploaded the excel file with the deferentially expressed me-
tabolites (with HMDB IDs and KEGG IDs) and the fold chang-
es information onto an online software Ingenuity Pathway 
Analysis (IPA) server (IPA, Ingenuity® Systems, http://www.
ingenuity.com). Then the bioinformatics analysis was per-
609
Tingting Chen et al., Early potential metabolic biomarkers of primary postpartum haemorrhage based on serum metabolomics
www. journals.viamedica.pl/ginekologia_polska
formed in accordance with operational guidelines, and the 
pathways analysis and networks analysis were carried out 
based on the knowledge sorted in the database of IPA. 
RESULTS
Identification of the Differential Metabolites
After removing those peaks with missing value in the 
two groups, a total of 1070 peaks of ESI+ and 670 peaks of 
ESI- were obtained from the acquired data. The PCA score 
plot showed a separation tendency between the control 
samples and PPH-pre-individuals, and the QC samples were 
clustered together illustrating the stability of the method 
through the whole run (Fig. 1). The PLS-DA score also showed 
the same separation trend between the control samples and 
PPH-pre-individuals (Fig. 2A, B), The permutation test of the 
model also showed that there was no overfitting, which 
proved that the model was reliable as shown in Figure 2C, D. 
Thirty-four metabolites with VIP > 1 and p < 0.05 calculated 
from the PLS-DA model and the Student’s t test (p < 0.05) 
were identified showed in Table 1. Some of metabolites 
showed increased concentration in PPH patients, such as 
LysoPC [20:4 (5Z, 8Z, 11Z, 14Z)], while several lipids, such as 
PI (O-20:0/0:0), PG (18:0/0:0), octadecanedioic acid and PC 
(15:0/0:0) were observed in decreased levels in the PPH-pre 
group. 
Metabolic Pathway Analysis with IPA
To study the relationship between metabolites, we 
used IPA software to conduct molecular pathways and 
networks analysis. The interaction Network Analysis of 
differential metabolites between the PPH-pre and control 
was shown in Figure 3. These metabolites were corre-
lated with mTOR signaling, acute phase response sign-
aling, AMPK signaling and eNOS signaling. IPA revealed 
that Myo-inositol Biosynthesis (1/9), Urate Biosynthesis 
(1/22), Guanosine Nucleotides Degradation (1/22), Ma-
turity Onset Diabetes of signaling (1/25), and Adeno-
sine Nucleotides Degradation (1/27) (as shown in Tab. 2) 
,which were the top five significantly changed pathways 
in PPH-pre-compared to control. The metabolic func-
tions analysis by IPA analysis were summarized in Table 2. 
The most significantly perturbed biological functions 
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Figure 1. Principle component analysis (PCA) scores plot and 3D scores plot discriminating the metabolic profiles in serum of PPH-pre and those 
in healthy control. (A), POS (two components model: R2X = 0.34, Q2 = 0.2). (B), NEG (two components model: R2X = 0.41, Q2 = 0.2); ■ — QC group; 
● — Healthy Control group; ▲ — PPH-pre group; PPH — Primary Postpartum haemorrhage; QC — Quality Control
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were connective Tissue Disorder (p = 6.02e-04-8.6e-05), 
Developmental Disorder (p = 8.60e-05-8.60e-05), Hema-
tological Diseases (p = 3.78e-02-8.60e-05), Hereditary 
Disorder (p = 8.60e-05-8.60e-05) and Inflammatory Dis-
eases (p = 1.21e-02-8.60e-05) (Tab. 2). The top 5 significant 
molecular and cellular functions were Free Radical Scav-
enging, Lipid metabolism, Small molecule biochemistry, 
Cellular Movement and Cell death and survival (Tab. 2). 
Then we performed pathway enrichment analysis of sig-
nificantly changed metabolites in PPH group, As shown 
in Figure 3 and Table 3, Glycerophospholipid metabo-
lism, D-Glutamine and D-glutamate metabolism, Purine 
metabolism, Linoleic acid metabolism, Citrate cycle (TCA 
cycle), Vitamin B6 metabolism.
DISCUSSION
PPH causes approximately 14 million deaths each 
year and the prevalence of PPH worldwide is between 
6% and 10%. The major reason for deaths of PPH is that 
related medical emergencies are not easy to early diagno-
sis even intervene immediately. Until now the diagnosis 
of PPH has been dependent on the estimate the amount 
of bleeding with low predictive ability and accuracy. 
Metabolomics is a relatively new tool for biomarkers 
identification for diseases like genomics, transcriptomics, 
and proteomics. We firstly applied metabolomics study on 
PPH using LC/MS to screen the predictive biomarkers of 
PPH. In our study, vaginal delivery pregnant women with-
out PPH and pregnant women with PPH were recruited, 
then we detected the metabolites of serum obtained 
prior to childbirth. In our study, 34 significantly altered 
metabolites in PPH-pre-group were identified. They were 
mainly involved in fatty acid, and glycerophospholipid 
metabolism. 
Fatty acids, especially the unsaturated derivatives, 
affect many physiological functions and a wide range 
of mechanisms [13]. In addition to the source of energy, 
polyunsaturated fatty acids (PUFA) also endow cell mem-
Figure 2. Partial least squares-discriminant analysis (PLS-DA) scores plot and permutation test for the model discriminating serum samples from 
PPH-pre group and healthy control; ● — Healthy Control group; ▲ — PPH-pre group; (A1) POS-PLS-DA scores plot. The model parameters were: 
R2Xcum = 0.34, R2Ycum = 0.87, Q2 = 0.89; (A2) NEG-PLS-DA scores plot. The model parameters were: R2Xcum = 0.44, R2Ycum = 0.89, Q2 = 0.87; (B1) 
A 999-times permutation test for the corresponding model. The Y-axis intercepts were: R2 (0, 0.55), Q2 (0, −0.13). (B2) A 999-times permutation test 
for the corresponding model. The Y-axis intercepts were: R2 (0, 0.52), Q2 (0, –0.12); PPH — Primary Postpartum haemorrhage
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branes with unique structural and functional properties, 
modulate cellular and intercellular communication and 
gene expression [14]. Certain fatty acids regulate tran-
scription by peroxisome proliferator activated receptor 
family (PPARs). PPARs may play a role in placental me-
tabolism, fetal development and preeclampsia [15, 16]. 
During pregnancy, fatty acids accumulated in developing 
tissues [17] and the supply of maternal PUFA is crucial 
for mothers and neonates [18, 19]. The γ-3 fatty acid 
can inhibit the thrombosis and reduce the incidence 
and mortality of cardiovascular diseases. Other research 
suggested that γ-3 fatty acid also could reduce the blood 
pressure, triglyceride concentration, and risk of vascular 
endothelial dysfunction [20, 21]. In our study, the fatty 
acids were decreased in PPH-pre, this may be the warn-
ing signal for PPH. Most importantly is that we may also 
give the pregnant women ω-3 fatty acids supplemental 
diet for prevent PPH.
Phospholipids are hydrolyzed to produce lysophos-
pholipids and free fatty acids. Lysophospholipids exists 
in biological fluids and plays an important role in cell 
proliferation, migration and survival [22, 23]. Lysophos-
Table 1. The potential biomarkers of PPH detected by UPLC-Q-TOF/MS and their variation tendency
RT Mass Name HMDB KEGG vip p PPH/Control
0.58 801.7194 SM (d17:1/24:0) HMDB0011695 – 1.72 0.01 0.47 
0.93 173.0046 Quinaldic acid HMDB0000842 C06325 2.00 0.00 0.24 
13.63 750.5649 PG (16:0/18:0) HMDB0010572 – 2.17 0.00 0.49 
14.24 757.5686 PC [20:2(11Z, 14Z)/14:0] HMDB0008328 C00157 1.83 0.02 1.60 
0.56 145.989 oxoglutarate HMDB0000208 C00026 1.86 0.02 1.13 
12.43 281.2718 Oleamide HMDB0002117 C19670 1.73 0.03 1.32 
4.14 145.0527 N-Butyrylglycine HMDB0000808 – 1.88 0.02 0.89 
10.11 543.3333 LysoPC [20:4 (5Z, 8Z, 11Z, 14Z)] HMDB0010395 C04230 1.57 0.04 1.58 
11.28 547.3641 LysoPC [20:2 (11Z, 14Z)] HMDB0010392 C04230 1.70 0.03 1.84 
9.65 517.3172 LysoPC [18:3 (6Z, 9Z, 12Z)] HMDB0010387 C04230 2.34 0.00 1.30 
2.26 119.0739 L-Threonine HMDB0000167 C00188 1.44 0.04 0.89 
1.45 161.0509 Indole-3-carboxylic acid HMDB0003320 C19837 1.54 0.04 1.39 
8.32 248.1988 hexadecatetraenoic acid – – 1.77 0.00 0.24 
12.20 413.3507 Heptadecanoyl carnitine HMDB0006210 – 1.70 0.03 0.44 
9.40 184.1462 hendecenoic acid – – 1.63 0.05 0.37 
10.68 196.146 dodecadienoic acid – – 1.83 0.02 0.38 
10.21 519.3365 1-Linoleoylglycerophosphocholine HMDB0010386 C04230 2.14 0.01 0.80 
1.24 168.0287 Uric acid HMDB0000289 C00366 1.32 0.04 2.00 
9.39 379.2497 Sphingosine-1-phosphate – – 1.75 0.00 0.83 
12.72 464.351 SM (d18:1/0:0) HMDB0006482 C03640 1.36 0.03 0.59 
9.65 539.324 PS (19:0/0:0) – – 1.89 0.00 2.17 
7.46 614.3683 PI (O-20:0/0:0) – – 1.94 0.00 0.76 
11.91 586.3609 PI (O-18:0/0:0) – – 1.50 0.02 0.81 
10.61 558.3299 PI (O-16:0/0:0) – – 1.41 0.03 0.79 
8.08 510.2843 PG [18:1 (9Z)/0:0] – – 1.48 0.02 0.70 
7.62 512.3004 PG (18:0/0:0) – – 1.30 0.04 0.81 
6.70 482.2532 PG [16:1 (9Z)/0:0] – – 1.53 0.01 0.41 
10.61 481.3185 PC (15:0/0:0) – – 1.80 0.00 0.73 
10.20 555.3109 Pateamine – – 2.44 0.00 0.71 
7.73 368.1668 PA (6:0/6:0) – – 1.84 0.00 3.96 
10.24 450.263 PA [19:1 (9Z)/0:0] – – 1.32 0.04 0.77 
11.50 314.2455 Octadecanedioic acid HMDB0000782 – 1.24 0.05 0.55 
0.66 60.0211 Urea HMDB0003344 C00266 1.38 0.03 0.71 
0.73 260.0293 D-Glucose 6-phosphate HMDB0001401 C00092 1.27 0.04 2.08 
612
Ginekologia Polska 2019, vol. 90, no. 10
www. journals.viamedica.pl/ginekologia_polska
Table 2. Summary of Biomarkers Function Analysis
Top canonical pathways p-value Overlap
Myo-inositol Biosynthesis 7.74e-04 11.1%,1/9
Urate Biosynthesis 1.89e-03 4.5%, 1/22
Guanosine Nucleotides Degradation 1.89e-03 4.5%, 1/22
Maturity Onset Diabetes of signaling 2.15e-03 4%, 1/25
Adenosine Nucleotides Degradation 2.32e-03 3.7%, 1/27
Diseases and bio functions p-value range Molecules
Connective Tissue Disorder 6.02e-04-8.6e-05 1
Developmental Disorder 8.60e-05-8.60e-05 1
Hematological Diseases 3.78e-02-8.60e-05 1
Hereditary Disorder 8.60e-05-8.60e-05 1
Inflammatory Diseases 1.21e-02-8.60e-05 1
Molecular and cellular functions p-value range Molecules
Free Radical Scavenging 8.58e-03-6.57e-05 2
Lipid metabolism 1.22e-02-1.26e-04 2
Small molecule biochemistry 3.98e-02-1.26e-04 2
Cellular Movement 2.08e-02-1.72e-04 1
Cell death and survival 2.92e-02-2.58e-04 1
ID Molecules in Network Score Focus Top Diseases and Functions
1
APOA1, ASB7, cholesterol sulfate, COL4A1, Collagentype VII, CPB2, CPN1, F13A1, F13B, factor 
XIII, FGA, FGB, FGG, Fibrin, Fibrinogen, glycosylphosphatidylinositol, GPLD1, HDL, Hmgn3, 
HSPG2, ITIH4, LAMA3, LAMB3, LPA, miR-18a-5p (and other miRNAs w/seed AAGGUGC), NID1, 
P38 MAPK,PDGF-DD, Pzp, SERPINF2, Stat3-Stat3, Tgf beta, TGFB1, TLL1, TLL2
27 10
Organismal Injury and 
Abnormalities, Hematological 
System Development and 
Function, Developmental Disorder
2
ABCB4, ACOX1, AIRE, C1QA, choline, CKMT1A/CKMT1B, CXCR6, CYCS,D-glucose, FST, FTL, G6PC, 
Gm15807/Hmgn5, GPD1, Hbb-b2,Hmgn3, IFNG, IL16, LAMA4, LAMB2, LTB, MAFK, Mbl1, MLXIPL, 
Mup1(includes others), NR1I2, NRF1, PEPCK, PLAC8, RETNLB, RORA, RORC, SCD, SMARCB1, TP53
9 4
Inflammatory Response, 
Cancer, Organismal Injury and 
Abnormalities
Figure 3. Summary of the pathway analysis of biomarkers of Primary Postpartum haemorrhage
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Table 3. Pathway analysis of biomarkers of Primary Postpartum haemorrhage
Pathway Name Match Status p -log (p) Holm p FDR Impact
Glycerophospholipid metabolism 2/39 0.012832 4.3558 1.0 0.9181 0.1037
D-Glutamine and D-glutamate metabolism 1/11 0.049237 3.0111 1.0 0.9181 0.0
Purine metabolism 2/92 0.06351 2.7566 1.0 0.9181 0.01763
Linoleic acid metabolism 1/15 0.066588 2.7092 1.0 0.9181 0.0
Citrate cycle (TCA cycle) 1/20 0.087871 2.4319 1.0 0.9181 0.08577
Alanine, aspartate and glutamate metabolism 1/24 0.10458 2.2578 1.0 0.9181 0.0
Sphingolipid metabolism 1/25 0.10871 2.219 1.0 0.9181 0.00191
Valine, leucine and isoleucine biosynthesis 1/27 0.11693 2.1462 1.0 0.9181 0.0
alpha-Linolenic acid metabolism 1/29 0.12507 2.0789 1.0 0.9181 0.0
Lysine biosynthesis 1/32 0.13716 1.9866 1.0 0.9181 0.0
Vitamin B6 metabolism 1/32 0.13716 1.9866 1.0 0.9181 0.01914
Inositol phosphate metabolism 1/39 0.16479 1.8031 1.0 0.9181 0.0
Butanoate metabolism 1/40 0.16867 1.7798 1.0 0.9181 0.0
Histidine metabolism 1/44 0.18402 1.6927 1.0 0.9181 0.0
Ascorbate and aldarate metabolism 1/45 0.18782 1.6723 1.0 0.9181 0.0
Glycine, serine and threonine metabolism 1/48 0.19912 1.6139 1.0 0.9181 0.09661
Glyoxylate and dicarboxylate metabolism 1/50 0.20657 1.5771 1.0 0.9181 0.0
Starch and sucrose metabolism 1/50 0.20657 1.5771 1.0 0.9181 3.1E-4
Pyrimidine metabolism 1/60 0.2429 1.4151 1.0 0.99993 0.0
Arachidonic acid metabolism 1/62 0.24998 1.3864 1.0 0.99993 0.0
Aminoacyl-tRNA biosynthesis 1/75 0.29457 1.2223 1.0 1.0 0.0
phatidylcholine (LPC) is a bioactive lysophospholipids, 
mainly produced by the action of phospholipase A2 (PLA2) 
enzyme on the plasma membrane. After cell uptake, the 
free LPC reaction produces PC or deacylation to produce 
FA and choline. These endogenous lysophosphatidates 
regulate the PPAR gamma function required for vascular 
wall pathology and metabolic related diseases. The imbal-
ance of PPAR gamma can induce cell function changes, 
including ROS production, NOS and cytokines expression. 
In our study, the level of PCs, PSs, PIs were decreased in the 
PPHand the lysoPCs were increased in the PPH, in which 
the latter may be cause the coagulation dysfunction in the 
PPH. According to our study, it may be useful to monitor 
the changes of lipids to assess the risk of PPH, especially 
for the lysoPCs.
Although the occurrence of PPH is associated with 
a variety of causes, in most cases, PPH is caused by bleeding 
from the site of the placenta, which is caused by uterine 
inertia [24, 25]. Due to high uterine artery blood flow at 
the end of pregnancy, uterine inertia can lead to severe 
bleeding. The PPH stepwise initiative management scheme 
can improve the prognosis. So far, there is no unified con-
clusion about the pathogenesis of PPH. In addition, we 
need to find markers for PPH risk prediction and find new 
precise mechanisms. According to our pathway analysis 
with IPA, these potential makers found in our study were 
related to mTOR signaling, acute phase response sign-
aling, AMPK signaling and eNOS signaling, as shown in 
Figure 4. These signaling pathways may provide guidance 
for further studies on the pathogenesis of postpartum 
hemorrhage.
CONCLUSIONS
In our study, we found the LysoPCs, PCs, PGs, PIs 
were effective biomarkers for predicating PPH. The dis-
turbed signaling pathways, mTOR signaling, acute phase 
response signaling, AMPK signaling and eNOS signaling 
might be related to the etiopathogenesis of PPH. Our 
study provided a valuable attempt to screen early di-
agnostic markers of PPH and to further understand its 
pathogenesis.
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